In order to ensure 2023 billing, testing must be activated before the end of the year, or within 30 days of proband sample collection (if sample was collected in 2023). For Exome, Genome, or Xpanded testing, if you do not expect parental samples to be received in time for testing to be activated with 2023 billing, please contact us at email@example.com to determine how to proceed.
IMPORTANT NOTICE: Taysha Gene Therapies Sponsored Testing Program
Please let this serve as a courtesy notice that the Taysha Gene Therapies Sponsored Testing Program is ending and GeneDx will no longer accept test orders for the program after November 10, 2023.
All GeneDx Genetic Test Reports resulting from test orders for GeneDx Test Code 737 submitted via the Taysha Gene Therapies Program that are received on or before November 10 will continue to be issued as usual, per the reporting preference(s) listed on the GeneDx Test Requisition Form, and within the normal turnaround time for GeneDx Test Code 737 (4 weeks). If you should have any questions regarding test orders submitted to GeneDx through the Taysha Gene Therapies Program, please continue to reach out to the BioPharma team here at GeneDx via firstname.lastname@example.org.
Testing for any orders submitted via the Taysha Gene Therapies Program that are received after November 10 will be placed on hold. Our GeneDx clinical team will reach out to discuss testing options. Of note: it will remain possible to order GeneDx’s Hereditary Neuropathy Panel (Test Code 737) via alternate billing options.
We value the trust that you have placed in GeneDx with your patient’s genetic testing and we look forward to seeing our relationship continue in other ways. If you should have any questions regarding other available tests here at GeneDx, please reach out to our Client Support team via email@example.com to be connected to your local GeneDx Sales Representative and/or Client Relations Manager.